Bortezomib相关论文
目的:探讨来那度胺联合硼替佐米及地塞米松（RVD）方案治疗新诊断多发性骨髓瘤（newly diagnosed multiple myeloma，NDMM）患者的疗效及安全......
Tumor cells undergoing immunogenic cell death (ICD) have emerged as an in situ therapeutic vaccine helping to activate a......
Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia S
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever disease caused by SFTSV,a newly disc......
...
pH-responsive drug delivery systems can retain the drug within the carrier and release it under mild acidic conditions [......
Chemotherapy plays an important role in the treatment of cancer,but the optimal clinical approach for chemotherapy has n......
Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was m
...
Bortezomib could down-regulate the expression of RANKL,inhibit cell proliferation and induce cell ap
目的 In spite of bortezomib being developed and demonstrated as a safe drug therapy for multiple myeloma(MM),the role of......
目的 Multiple myeloma(MM)is a hematopoietic malignancy characterized by theclonal proliferation of antibody-secreting pl......
PHLPP sensitizes multiple myeloma cells to bortezomib by increasing LAMP2 Running title:PHLPP in BTZ
Objective Owing to the use of proteasome inhibitor such as bortezomib(BTZ),clinical outcomes of patients with multiple m......
...
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients with relapsed mu
Objective: ENDEAVOR (NCT01568866) is comparing Kd with Vd in patients with RMM.The primary endpoint is PFS.Secondary end......
目的 This study aimed to investigate the chemotherapeutic effect and underlying mechanism of Bortezomib on gliomas,alone......
Sensitization of multiple myeloma cells to natural killer cell and gamma delta T cells-mediated cyto
Background aims: Bortezomib is a proteasome inhibitor, which has a direct effect in multiple myeloma (MM) cells and has ......
Chemo-free salvage regimen is superior to conventional chemotherapy in patients with relapsed/refrac
Objective Subcutaneous panniculitis-like T-cell lymphoma(SPTCL)is a rare disease entity which predominantly localizes in......
...
Upregulation of NLRP1 Inflammasome by STAT3 Activation and STAT3-dependent Histone Acetylation in DR
Background.Bortezomib(BTZ)is the frontline chemotherapeutic drug for multiple myeloma.However,BTZ carries a severeside e......
STAT3 mediated NLRP3 activation in the microglia and neuron of spinal dorsal horn contributes to Bor
Background.Bortezomib(BTZ)is a regularly used first-line chemotherapeutic drug for the therapy of refractory multiple my......
目的观察Bortezomib对胃癌细胞周期、增殖、凋亡及核因子-κB(NF-κB)的影响。方法采用噻唑蓝(MTT)法检测Bortezomib对细胞生长的......
Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refracto
...
Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferenti
...
OBJECTIVE The proteasome inhibitor bortezomib(BTZ)is a first-line anti-multi⁃ple myeloma drug.BTZ-induced peripheral ne......
Proteasome inhibitors,bortezomib(BTZ),and carfilzomib(CFZ)are approved drugs for hematological malignancies,but lack ant......
目的:评估沙利度胺和硼替佐米在初诊多发性骨髓瘤(MM)患者维持治疗中的疗效和不良反应。方法:回顾性分析比较使用硼替佐米维持治疗......
2008年6月23日,美国FDA批准bortezomib(商品名:Velcade)用于未经任何治疗的多发性骨髓瘤患者。该项新适应证的批准为该病患者的早......
淋巴细胞特异性蛋白-1(LSP1)在部分多发性骨髓瘤中表达升高,但其在肿瘤中的作用仍知之甚少.研究了LSP1在多发性骨髓瘤中抗新型抗肿......
多发性骨髓瘤（ MM）伴发周围神经病变主要表现为进行性、对称性的四肢远端感觉及运动障碍。目前对于周围神经病变发生的机制尚不清楚，......
目的 探讨减低剂量及标准剂量硼替佐米联合阿霉素、地塞米松治疗不同类型多发性骨髓瘤(MM)的近期疗效及安全性.方法 对52例初诊、......
目的 观察硼替佐米对胰腺癌细胞BxPC3、SW1990增殖、凋亡的影响,探讨硼替佐米杀伤癌细胞的可能机制.方法 应用1、10、50、100、500......
目的初步评价硼替佐米皮下注射治疗POEMS综合征的疗效和安全性。方法对首都医科大学宣武医院血液科2013年1月以来收治的初诊POEMS......
AIM: To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinom......
Objective: The aim of our study was to investigate the effect of bertezomib in combination with arsenic trioxide (As2O3)......
胃肠道间质瘤(gastrointestinal stromal tumors,GIST)是多发于胃部和小肠的消化道间质肿瘤。约有80%-85%的GIST存在酪氨酸激酶受......
目的 观察以硼替佐米为主的联合化疗方案加或不加造血干细胞移植(SCT)治疗多发性骨髓瘤(multiple myeloma,MM)患者的疗效及不良反......
本研究探讨硼替佐米(Bor)单用及与三氧化二砷(As2O3)联合应用对多发性骨髓瘤(MM)细胞株KM3细胞凋亡的影响及其相关机制.采用MTT法......
美国FDA已经批准Millennium公司的蛋白酶抑制剂bortezomib(Velcade)作为顽固性或易复发的多发性骨髓瘤的治疗药物。公司表示 ,该药......
Bortezomib(曾用名 :PS 341)是一种二肽基硼酸化合物 ,能以高效、专一的方式抑制蛋白酶体。美国马萨诸塞州坎布里奇 (Cambridge)的......
目的探讨蛋白酶体抑制剂硼替佐米在逆转人结肠癌细胞获得性肿瘤坏死因子相关凋亡诱导配体(TRAIL)耐药中的作用及机制。方法在硼替......
目的:综合评价国内硼替佐米联合地塞米松(BD方案)治疗多发性骨髓瘤(MM)的疗效和安全性.方法:计算机检索2005-2011中国学术期刊全文......
多发性骨髓瘤(multiple myeloma,MM)是常见的造血系统恶性肿瘤之一,随着年龄的增长其发病数也增加,特别是70～80岁,甚至在大于80岁的......
目的:观察DVD方案(脂质体阿霉素、长春新碱或长春地辛、地塞米松)和PAD方案(硼替佐米、脂质体阿霉素、地塞米松)治疗初治多发性骨......
华氏巨球蛋白血症(Waldenstr(o)m's macro-globulinemia,WM)是B淋巴细胞增殖性疾病,其特点是骨髓中出现浆细胞样淋巴细胞浸润,血......
目的:研究以硼替佐米为主的联合化疗对多发性骨髓瘤(MM)的疗效及其不良反应.方法:回顾性分析52例MM患者,其中42例接受以硼替佐米为......
目的:分析含硼替佐米诱导治疗序贯自体造血干细胞移植(ASCT)的治疗方案对初诊时合并髓外病变(EMD)的多发性骨髓瘤(MM)患者预后的影......
抗体介导的排斥反应(antibody-mediated rejection,AMR)是影响肾移植术后存活的重要因素之一。硼替佐米作为高选择性蛋白酶抑......
